Clinical trial
ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
NCT00404924 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00404924 |
|---|---|
| Title | ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures |
| Official title | A Phase III Study to Assess the Efficacy of ZD6474 (ZACTIMA™) Plus Best Supportive Care Versus Best Supportive Care in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer After Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Carcinoma |
| Intervention type | Drug, Other |
| Interventions | ZD6474 (vandetanib), Best Supportive Care |
| Enrollment | 1,140 |
| Start date | Nov 1, 2006 |
| Primary completion | Oct 1, 2009 |
| Completion | Nov 1, 2014 |
| First posted | Nov 29, 2006 |
| Last update posted | Sep 30, 2016 |
| Countries | Argentina, Australia, Austria, Belgium, Canada, China, France, Germany, Hong Kong, Israel, Italy, Mexico and 10 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: